{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:35:10Z","timestamp":1782462910433,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["5255"],"award-info":[{"award-number":["5255"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["10361"],"award-info":[{"award-number":["10361"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.vaccine.2015.01.028","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T13:45:20Z","timestamp":1421675120000},"page":"977-984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine"],"prefix":"10.1016","volume":"33","author":[{"given":"Pawe\u0142 M.","family":"B\u0119czkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navapon","family":"Techakriengkrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Willett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J.","family":"Hosie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.01.028_bib0290","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jfms.2009.05.019","article-title":"Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany","volume":"11","author":"Gleich","year":"2009","journal-title":"J Feline Med Surg"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0295","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/00002030-200107060-00004","article-title":"Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates","volume":"15","author":"Pu","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.vetmic.2005.02.014","article-title":"Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats","volume":"108","author":"Kusuhara","year":"2005","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0305","first-page":"9","article-title":"Feline leukemia and feline immunodeficiency virus in Canada\u2014a comment","volume":"53","author":"Doornenbal","year":"2012","journal-title":"Can Vet J"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0310","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1016\/j.vaccine.2011.06.085","article-title":"Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review","volume":"29","author":"Girard","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0315","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jfms.2009.05.006","article-title":"Feline immunodeficiency. ABCD guidelines on prevention and management","volume":"11","author":"Hosie","year":"2009","journal-title":"J Feline Med Surg"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature08757","article-title":"Targeting early infection to prevent HIV-1 mucosal transmission","volume":"464","author":"Haase","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0325","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.clpt.6100408","article-title":"HIV\/\/AIDS vaccines: 2007","volume":"82","author":"Robinson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0330","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/icb.2010.118","article-title":"Human immunodeficiency virus-1 vaccine design: where do we go nowquest","volume":"89","author":"Wijesundara","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0335","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0340","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/428405","article-title":"Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","volume":"191","author":"Gilbert","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0345","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Group BVE: randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0350","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0355","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0360","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.01.028_bib0365","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study)","volume":"206","author":"Duerr","year":"2009","journal-title":"J Infect Dis"},{"issue":"4\u20135","key":"10.1016\/j.vaccine.2015.01.028_bib0370","first-page":"7","article-title":"Raft of results energizes researchers","volume":"13","author":"Kresge","year":"2009","journal-title":"IAVI Rep"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1128\/CMR.8.1.87","article-title":"Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen","volume":"8","author":"Bendinelli","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0380","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0264-410X(97)00056-X","article-title":"Perspectives on FIV vaccine development","volume":"15","author":"Elyar","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1135(99)00096-6","article-title":"Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge","volume":"69","author":"Hesselink","year":"1999","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-2427(02)00227-1","article-title":"FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review","volume":"90","author":"Uhl","year":"2002","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0395","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/vr.158.16.561","article-title":"Limited efficacy of an inactivated feline immunodeficiency virus vaccine","volume":"158","author":"Dunham","year":"2006","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0400","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1089\/hum.1996.7.10-1205","article-title":"An improved plasmid DNA expression vector for direct injection into skeletal muscle","volume":"7","author":"Hartikka","year":"1996","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0405","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0410","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0415","article-title":"Rapid evolution of the env gene leader sequence in cats naturally infected with feline immunodeficiency virus (FIV)","author":"B\u0119czkowski","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0420","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1128\/JVI.69.2.1253-1255.1995","article-title":"Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines","volume":"69","author":"Hosie","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/aid.1995.11.531","article-title":"Analysis of a feline immunodeficiency virus provirus reveals patterns of gene sequence conservation distinct from human immunodeficiency virus type 1","volume":"11","author":"Sodora","year":"1995","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0430","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/JVI.64.10.4605-4613.1990","article-title":"Comparison of two host cell range variants of feline immunodeficiency virus","volume":"64","author":"Phillips","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0435","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/JVI.69.10.6149-6157.1995","article-title":"Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage","volume":"69","author":"Diehl","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0440","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1128\/JVI.01064-07","article-title":"Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus","volume":"81","author":"Giannecchini","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0445","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/JVI.70.5.3011-3017.1996","article-title":"Molecularly cloned feline immunodeficiency virus NCSU1 JSY3 induces immunodeficiency in specific-pathogen-free cats","volume":"70","author":"Yang","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0450","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/JVI.02638-09","article-title":"Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus","volume":"84","author":"Pistello","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0455","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1128\/JVI.80.7.3386-3394.2006","article-title":"Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus","volume":"80","author":"Willett","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0460","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0465","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"Tamura","year":"2011","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0470","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1073\/pnas.0404206101","article-title":"Prospects for inferring very large phylogenies by using the neighbor-joining method","volume":"101","author":"Tamura","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0475","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/bioinformatics\/btq429","article-title":"Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology","volume":"26","author":"Delport","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0480","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/molbev\/msl051","article-title":"Automated phylogenetic detection of recombination using a genetic algorithm","volume":"23","author":"Kosakovsky Pond","year":"2006","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0485","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/03610927808827599","article-title":"Further analysts of the data by akaike's information criterion and the finite corrections","volume":"7","author":"Sugiura","year":"1978","journal-title":"Commun Stat\u2014Theory Methods"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0490","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/JVI.73.1.152-160.1999","article-title":"Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination","volume":"73","author":"Lole","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0495","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.coviro.2013.08.003","article-title":"The virus-receptor interaction in the replication of feline immunodeficiency virus (FIV)","volume":"3","author":"Willett","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0500","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1079\/AHR200487","article-title":"Efficacy and safety of a feline immunodeficiency virus vaccine","volume":"5","author":"Huang","year":"2004","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0505","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1128\/JVI.00722-06","article-title":"Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus","volume":"80","author":"Willett","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0510","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12977-014-0095-7","article-title":"Emergence of CD134 cysteine-rich domain 2 (CRD2)-independent strains of feline immunodeficiency virus (FIV) is associated with disease progression in naturally infected cats","volume":"11","author":"B\u0119czkowski","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0515","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3390\/v3101870","article-title":"Feline immunodeficiency virus (FIV) neutralization: a review","volume":"3","author":"Hosie","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0520","doi-asserted-by":"crossref","first-page":"17407","DOI":"10.7448\/IAS.15.2.17407","article-title":"The changing face of HIV vaccine research","volume":"15","author":"Kwong","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0525","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0530","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.01.028_bib0535","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.vaccine.2013.05.024","article-title":"Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0540","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11904-009-0036-6","article-title":"Role of humoral immunity in host defense against HIV","volume":"7","author":"Baum","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0545","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.vetimm.2008.09.005","article-title":"Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA","volume":"126","author":"Huisman","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0550","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.1128\/JVI.77.13.7663-7668.2003","article-title":"Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0555","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(07)61702-4","article-title":"STEP study: disappointing, but not a failure","volume":"370","author":"Editorial","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0560","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e3180377b5b","article-title":"Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay","volume":"45","author":"Dubey","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0565","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.vaccine.2004.05.032","article-title":"Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine","volume":"23","author":"Omori","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.028_bib0570","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12977-014-0080-1","article-title":"Feline immunodeficiency virus (FIV) env recombinants are common in natural infections","volume":"11","author":"B\u0119czkowski","year":"2014","journal-title":"Retrovirology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T03:10:42Z","timestamp":1598670642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1500047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0264410X1500047X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}